Spots Global Cancer Trial Database for Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
Official Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Study ID: NCT03519230
Conditions
Study Description
Brief Summary: To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking University First Hospital, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
The First Bethune Hospital of Jilin University, Jilin, Changchun, China
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
The First Hospital Affiliated to AMU(Southwest Hospital), Chongqing, Chongqing, China
Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital& Oncology Medical College, Nanning, Guangxi, China
The First Affiliate Hospital of Guangzhou Medical University, Guangzhou, Guangzhou, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
Jilin Cancer Hospital, Changchun, Jilin, China
The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Yantai Yuhuangding Hospital, Yantai, Shandong, China
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China
West China Hospital Sichuan University, Chengdu, Sichuan, China
Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, Tianjin, China
Tianjin Medical University Cancer institute & Hospital, Tianjin, Tianjin, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Ding Ma, PhD
Affiliation: Tongji Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
